Patients with platinum- and paclitaxel-refractory ovarian cancer confined to the peritoneal cavity received intraperitoneally seven doses of MV-CEA, ranging from 103 to 109 TCID50, six times monthly. This evidence concerns the gene CEACAM5 and ovarian carcinoma.